273 related articles for article (PubMed ID: 28666474)
41. Heparin-free renal replacement therapy for chronic hemodialyzed patients at high risk for bleeding: a comparison of on-line predilution hemodiafiltration with conventional hemodialysis.
Brunot V; Serre JE; Mourad G; Klouche K; Pernin V
Hemodial Int; 2018 Oct; 22(4):463-473. PubMed ID: 29745004
[TBL] [Abstract][Full Text] [Related]
42. Comparison of two dialysers (AN69ST vs. FX100) for heparin-free dialysis in patients with oral anticoagulation.
Kodras K; Benesch T; Neumann I; Haas M
Blood Purif; 2008; 26(3):226-30. PubMed ID: 18305385
[TBL] [Abstract][Full Text] [Related]
43. Circuit life versus bleeding risk: the impact of achieved activated partial thromboplastin time versus achieved filtration fraction.
MacEwen C; Watkinson P; Winearls C
Ther Apher Dial; 2015 Jun; 19(3):259-66. PubMed ID: 25511624
[TBL] [Abstract][Full Text] [Related]
44. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study.
de Pont AC; Oudemans-van Straaten HM; Roozendaal KJ; Zandstra DF
Crit Care Med; 2000 Feb; 28(2):421-5. PubMed ID: 10708177
[TBL] [Abstract][Full Text] [Related]
45. Beta 2-microglobulin elimination characteristics during hemofiltration with acrylonitrile and polysulfone membrane hemofilters.
Kandus A; Ponikvar R; Drinovec J; Pavlin K; Ivanovich P
Int J Artif Organs; 1990 Apr; 13(4):200-4. PubMed ID: 2197235
[TBL] [Abstract][Full Text] [Related]
46. Myoglobin clearance and removal during continuous venovenous hemofiltration.
Amyot SL; Leblanc M; Thibeault Y; Geadah D; Cardinal J
Intensive Care Med; 1999 Oct; 25(10):1169-72. PubMed ID: 10551978
[TBL] [Abstract][Full Text] [Related]
47. Use of saline flush to prevent filter clotting in continuous renal replacement therapy without anticoagulant.
Panphanpho S; Naowapanich S; Ratanarat R
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S105-10. PubMed ID: 21721435
[TBL] [Abstract][Full Text] [Related]
48. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
[TBL] [Abstract][Full Text] [Related]
49. Use of argatroban: experiences in continuous renal replacement therapy in critically ill patients after cardiac surgery.
Klingele M; Bomberg H; Lerner-Gräber A; Fliser D; Poppleton A; Schäfers HJ; Groesdonk HV
J Thorac Cardiovasc Surg; 2014 Jun; 147(6):1918-24. PubMed ID: 24485959
[TBL] [Abstract][Full Text] [Related]
50. AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study.
Hirayama T; Nosaka N; Okawa Y; Ushio S; Kitamura Y; Sendo T; Ugawa T; Nakao A
J Intensive Care; 2017; 5():46. PubMed ID: 28729905
[TBL] [Abstract][Full Text] [Related]
51. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.
Birnbaum J; Spies CD; Klotz E; Hein OV; Morgera S; Schink T; Ziemer S; Grund MS; Saalmann R; Kox WJ; Lehmann C
Ren Fail; 2007; 29(3):271-7. PubMed ID: 17497439
[TBL] [Abstract][Full Text] [Related]
52. Effects of argatroban as an anticoagulant for intermittent veno-venous hemofiltration (IVVH) in patients at high risk of bleeding.
Sun X; Chen Y; Xiao Q; Wang Y; Zhou J; Ma Z; Xiang J; Chen X
Nephrol Dial Transplant; 2011 Sep; 26(9):2954-9. PubMed ID: 21303963
[TBL] [Abstract][Full Text] [Related]
53. Epoprostenol (Prostacyclin Analog) as a Sole Anticoagulant in Continuous Renal Replacement Therapy for Critically Ill Children With Liver Disease: Single-Center Retrospective Study, 2010-2019.
Deep A; Alexander EC; Khatri A; Kumari N; Sudheendhra K; Patel P; Joarder A; Elghuwael I
Pediatr Crit Care Med; 2024 Jan; 25(1):15-23. PubMed ID: 38169336
[TBL] [Abstract][Full Text] [Related]
54. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial.
Kozek-Langenecker SA; Spiss CK; Gamsjäger T; Domenig C; Zimpfer M
Wien Klin Wochenschr; 2002 Feb; 114(3):96-101. PubMed ID: 12060975
[TBL] [Abstract][Full Text] [Related]
55. Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomized controlled trial (AKIKI).
Gaudry S; Hajage D; Schortgen F; Martin-Lefevre L; Tubach F; Pons B; Boulet E; Boyer A; Lerolle N; Chevrel G; Carpentier D; Lautrette A; Bretagnol A; Mayaux J; Thirion M; Markowicz P; Thomas G; Dellamonica J; Richecoeur J; Darmon M; de Prost N; Yonis H; Megarbane B; Loubières Y; Blayau C; Maizel J; Zuber B; Nseir S; Bigé N; Hoffmann I; Ricard JD; Dreyfuss D
Trials; 2015 Apr; 16():170. PubMed ID: 25902813
[TBL] [Abstract][Full Text] [Related]
56. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.
Kalb R; Kram R; Morgera S; Slowinski T; Kindgen-Milles D
Ther Apher Dial; 2013 Apr; 17(2):202-12. PubMed ID: 23551677
[TBL] [Abstract][Full Text] [Related]
57. Citrate clearance in children receiving continuous venovenous renal replacement therapy.
Chadha V; Garg U; Warady BA; Alon US
Pediatr Nephrol; 2002 Oct; 17(10):819-24. PubMed ID: 12376810
[TBL] [Abstract][Full Text] [Related]
58. Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways.
Salmon J; Cardigan R; Mackie I; Cohen SL; Machin S; Singer M
Intensive Care Med; 1997 Jan; 23(1):38-43. PubMed ID: 9037638
[TBL] [Abstract][Full Text] [Related]
59. Randomised trial of software algorithm driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the Filter Life in Renal Replacement Therapy pilot trial.
Brain MJ; Roodenburg OS; Adams N; McCracken P; Hockings L; Musgrave S; Butt W; Scheinkestel C
Crit Care Resusc; 2014 Jun; 16(2):131-7. PubMed ID: 24888284
[TBL] [Abstract][Full Text] [Related]
60. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
